Free Trial
NASDAQ:MGX

Metagenomi Q1 2024 Earnings Report

Metagenomi logo
$1.67 +0.15 (+9.87%)
Closing price 04:00 PM Eastern
Extended Trading
$1.66 -0.01 (-0.60%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Metagenomi EPS Results

Actual EPS
-$1.19
Consensus EPS
-$0.95
Beat/Miss
Missed by -$0.24
One Year Ago EPS
N/A

Metagenomi Revenue Results

Actual Revenue
$11.16 million
Expected Revenue
$8.30 million
Beat/Miss
Beat by +$2.86 million
YoY Revenue Growth
N/A

Metagenomi Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Tuesday, May 14, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Metagenomi's Q1 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled on Wednesday, May 14, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Metagenomi Earnings Headlines

Metagenomi Leads The Charge With These 3 Penny Stocks
Metagenomi price target lowered to $7 from $14 at H.C. Wainwright
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
See More Metagenomi Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Metagenomi? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Metagenomi and other key companies, straight to your email.

About Metagenomi

Metagenomi (NASDAQ:MGX), a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

View Metagenomi Profile

More Earnings Resources from MarketBeat